The rarity of CMMRD and its diverse tumor features pose both a diagnostic and managerial challenge. Our patient was first diagnosed as adenomatous polyps with low-grade dysplasia. Based on retrospective research on 288 pediatric patients with coloscopic-proved polyps, isolated juvenile polyps were the most frequent histopathological type while juvenile polyposis syndrome, Peutz-Jeghers syndrome, familial adenomatosis polyposis (FAP), and other cancer predisposition syndromes accounted for the rest kinds of tumorous polyps [3]. In fact, the condition that a pediatric patient was diagnosed with adenomatous polyps other than juvenile polyps presented a necessity for evaluation for inherited polyposis syndrome. More importantly, the CALMs found were highly reminiscent of an accompanying genetic condition. The most common condition associated with CALMs is neurofibromatosis type 1 (NF-1), which also has other features, such as skin-fold freckling, iris Lisch nodules, cutaneous and subcutaneous neurofibromas, and importantly, CNS gliomas [4]. CMMRD patients may present with other diagnostic features of NF-1, and these overlapped phenotypes lead to misdiagnosis of CMMRD as NF-1 if only based on clinical examination. Given that CALMs are the most common non-neoplastic manifestation of CMMRD, and the coupling polyps containing adenomatous change are considered major cancer precursor lesions, attention should be paid to the MMR defect. Unfortunately, the diagnosis was not made till the occurrence of brain gliomas because of the lack of a fully developed polyposis phenotype.
Gliomas, especially high-grade gliomas, constitute the largest proportion of brain tumors. Others include supratentorial primitive neuroectodermal tumors and medulloblastomas. Followed by the current consensus suggesting a genetic analysis be performed in the case of high-grade tumors including gliomas in the pediatric groups, sequencing analysis of MMR genes was done which demonstrated a novel homozygous loss-of-function mutation NM_00535.5:c.1577delA (p.Asp526fs) in PMS2. In the process of detecting homozygous mutation of the PMS2 gene, we intercepted the 100 bp on both sides of the mutation site and analyzed them by high-throughput sequencing. The result showed it was inconsistent with the PMS2CL, the homologous pseudogene of PMS2, indicating that the mutation is not PMS2CL [5]. Considering that the patient had gliomas and CRC with MSI-H at a very young age, this frameshift mutation was deemed a driver mutation in her carcinogenesis and was the most likely cause of the phenotype. The cancer spectrum in CMMRD appeared to be related to the MMR gene mutated [6]. PMS2 mutations are most frequent in CMMRD and responsible for almost 60% of cases, followed by MLH1, MSH6 and MSH2. Patients having homozygous conditions in PMS2 develop brain tumors within their first decade of life [6]. The identification of homozygous PMS2 mutation status led to a necessity of gene surveillance of familial members. Two variants of the PMS2 gene, S260S and A96A, were found not only in the patient’s mother aged 45 but the younger brother aged 5. These variants are nucleotide exchanges that are synonymous at protein level, meaning they do not cause changes of amino acids and have no apparent effect on the encoded protein. The patient’s brother also had two missense variants, K541E and R20Q, which were analyzed by Polyphen2 and predicted to be benign with a score of 0.000 and 0.164, respectively (Table 1). Also, two different in silico databases (ClinVar and SNPs&GO) consistently predicted that the known variants K541E and R20Q are not associated with MMR and LS. The patient’s mother and younger brother had no signs of malignancies or colorectal polyps, but the younger brother with two missense variants in the PMS2 had multiple CALMs, so close surveillances including radiological, endoscopic and hematological screening have been recommended.
Intriguingly and rarely, this patient is homozygous for mutation p.Asp526fs but the mother is not a carrier of this mutation. And the father died of acute myocardial infarction at the age of 44, and there is no detailed data on whether her father had LS, in which LS patients frequently develop colorectal cancer before the age of 50 (average age at onset of disease: 45 years) [7]. After the maternity confirmed, we have performed germline copy number aberrations (CNAs) analysis and determined that the loss of heterozygosity (LOH) has occurred newly in the patient. Sequencing data (FASTQ) of WBC samples collected from 68 healthy individuals were used to construct a "reference panel", which underwent the same experiment and analysis procedures to ensure that it was comparable to the patient's WBC sample. For each reference sample, targeted genomic regions on chromosome 7 were binned into 100 bp. We then applied Circular Binary Segmentation (CBS) on depth ratio between the patient sample and reference. The results showed that c.1577delA resides in the patient's LOH genomic region (Fig. 2A), and c.1621A>G and c.59G>A are located in the younger brother's LOH and diploid regions, respectively (Fig. 2B). These present the diagnostic challenges and difficulties in identifying familial PMS2 mutations.
Close colonoscopic surveillance has shown vast advantages by decreasing the modality and mortality of CRC for patients with cancer-prone polyposis syndromes [8]. Generally, colonoscopic screening recommendations depend on risk stratification including the age when colorectum polyps develop, the interval at which polyps grow, the frequency and rate at which polyps may progress to cancer [8]. Those with likely or confirmed hereditary CRC syndromes belong to high-risk patients and should initiate screening earlier and undergo surveillance at shorter intervals than average or increased risk individuals. For CMMRD patients, due to the faster progression of polyp to cancer development, colonoscopy is recommended beginning at the first decade of life or earlier and with a shorter screening interval of 6 months [1]. Video-capsule endoscopy and double-balloon enteroscopy are also recommended to identify small bowel adenomas or cancers. Unfortunately, the patient didn’t comply with surveillance protocols until the development of left-side CRC. Except for the delay in making CMMRD diagnosis, her reluctance to undergo interval screening was the main reason.
Current knowledge of therapeutic strategies and their outcomes in CMMRD are limited because the related information comes from limited research of individual patients or small patient series. Due to the high mutation rate caused by diminished replication repair, rapid onset and frequent recurrence of cancers may occur despite standard-of-care treatment. Chemotherapy remains a frontline treatment based on various phenotypes of CMMRD cancer, but effective chemotherapy drugs are still lacking. This is due to severe drug toxicity in children, MMR deficient associated resistance to chemotherapeutics, and the ability to accelerate somatic mutations which cause an increased risk of secondary tumors. Recently, there is growing evidence to support immunotherapy in the treatment of CMMRD cancers. Immune checkpoint inhibitors, such as programmed cell death-1 blockers, have been found to produce a successful clinical response in CMMRD patients holding MSI-H/hypermutated tumors [9]. Hypermutated tumors lead to the production of truncated protein products termed neoantigens. The preliminary efficacy of neoantigen-based vaccines has been observed in LS patients that show neoantigen-specific immune responses [10]. This creates fair expectations on this class of agents as an effective therapeutic approach for CMMRD. More importantly, given that intensive surveillance may not guarantee detection at a curable stage, preventive treatment strategy represents a promising avenue for CMMRD management. Aspirin has been shown potential in CMMRD patients for chemoprevention against MSI-H CRC, ovarian cancer, and T cell lymphoma [11]. The underlying mechanism is explained by nitric oxide-mediated apoptosis of cells of an MSI phenotype while further clarity is required [12].
Taken together, the diagnosis and treatments of a Chinese girl with CMMRD were outlined and the newly found mutation in PMS2 will update our understanding of genomic variants which contributes to enhanced patient management. Importantly, for pediatric patients with CR adenomas, especially those with CALMs, we recommended the integration of molecular (or genomic) testing into routine clinical care to identify CMMRD.